Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Renalytix's Debt-to-Equity or its related term are showing as below:
STU:2O9'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.99 Med: 0 Max: 3.18
Current: -4.84
During the past 8 years, the highest Debt-to-Equity Ratio of Renalytix was 3.18. The lowest was -5.99. And the median was 0.00.
STU:2O9's Debt-to-Equity is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 0.43
vs STU:2O9: -4.84
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Renalytix Debt-to-Equity Related Terms
Renalytix Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Renalytix's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2O9 vs VEEV, BTSG, TEM: Debt-to-Equity Comparison
For the Health Information Services subindustry, Renalytix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renalytix Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Renalytix's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renalytix (STU:2O9) has a Debt-to-Equity of -5.99 as of Dec. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Renalytix and its competitors. According to the industry distribution chart, Renalytix ranks #999999 out of 565 companies in the Healthcare Providers & Services industry.
Is Renalytix's Debt-to-Equity too high?
Renalytix's current Debt-to-Equity is -5.99. Based on the distribution chart, Renalytix ranks #999999 out of 565 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Renalytix has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Renalytix's Debt-to-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Renalytix ranks #999999 out of 565 companies for Debt-to-Equity. This places Renalytix in the lower half of its industry. The industry median Debt-to-Equity is 0.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.43, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Renalytix and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renalytix's current Debt-to-Equity is -5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Renalytix (STU:2O9) has a current Debt-to-Equity of -5.99. The stock's GF Value™ is €0.04, compared to a current price of €0.07 — trading 70% above its estimated fair value. The current Debt-to-Equity is -5.99. Renalytix's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Renalytix (STU:2O9), the current Debt-to-Equity is -5.99 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renalytix (STU:2O9) Overvalued in 2026?
Based on GuruFocus' analysis, Renalytix stock appears to be overvalued.
The current stock price of €0.07 is trading 70% above its estimated GF Value™ of €0.04.
Key valuation signals for STU:2O9:
Debt-to-Equity: -5.99
GF Value™: €0.04 vs. price of €0.07 (70% above fair value)
No single metric tells the full story. See the STU:2O9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
12GF Score
Get the complete analysis for STU:2O9
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2O9 has been successfully added to your 
